SHR0302 tablets with or without SHR0302 base gel for non-segmental vitiligo

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial compares oral SHR0302 tablets given alone or in combination with an SHR0302 base gel against matching placebos in adults with non-segmental vitiligo. Participants must stop other vitiligo treatments and therapeutic cosmetic products and meet age and contraception requirements. The study uses active and placebo tablets and gels to measure repigmentation outcomes and collect safety data. The trial is conducted at a dermatology center in Jinan, China, with clinical assessments and adverse event monitoring over the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Sign the informed consent form before the clinical trial.
2. On the day of signing the informed consent form, the age must be between 18 and 75 years old (inclusive), and it can be either male or female.
3. The subjects and their partners had no intention of having children during the study period and within one month after the administration of the drug, did not donate sperm or eggs, and voluntarily adopted effective contraceptive measures. The serum pregnancy test results of the female subjects must be negative and they must not be in the lactation period.
4. During the screening process, it was clinically diagnosed as non-segmental vitiligo.
5. Throughout the entire research process, the participants agreed to stop using all treatments related to vitiligo as well as any cosmetic products with therapeutic effects.

Exclusion Criteria:

1. Subjects diagnosed with segmental, mixed or undifferentiated vitiligo; or subjects previously diagnosed with other skin pigmentation disorders.
2. When the facial skin lesions caused by vitiligo cover more than 33% of the area with white hair.
3. During the screening period or at the baseline, there were other active skin lesions or skin infections that might interfere with the use of the study drug or the evaluation of the drug's efficacy.
4. Subjects with a history of related infections/communicable diseases or infection/contagion history.
5. Known or suspected history of immunosuppression.
6. Tuberculosis (TB) or latent tuberculosis infection.
7. Positive for human immunodeficiency virus antibody HIV-Ab, positive for syphilis-specific antibody, positive for hepatitis C virus antibody HCV-Ab, or hepatitis B virus (HBV) infection.
8. Subjects who have malignant tumors or have a history of malignant tumors.
9. Abnormal thyroid function, with a history of thrombotic diseases within the previous 12 months, and having experienced a cardiovascular or cerebrovascular event that required hospitalization within the previous 12 months.
10. There are serious abnormalities in the cardiovascular, mental, renal, liver, immune, gastrointestinal, urogenital, nervous, skeletal-muscular, skin, sensory, endocrine or hematological systems.
11. Pregnant women, lactating women, or female participants who plan to become pregnant during the study period.
12. Those who are known to be allergic to the test drug or any component of the test drug.

Where it's running

• Dermatology Hospital affiliated to Shandong First Medical University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Hui Wang
• Email: hui.wang.hw119@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of ACT-777991 in adults with non-segmental vitiligo

  This study tests whether ACT-777991 can help restore skin color in adults with non-segmental vitiligo, compared to placebo.

  Recruiting Phase 2 Idorsia Pharmaceuticals Ltd. · Los Angeles, California and 4 other locations · NCT07667569

• Different doses of GIA632 for adults with non-segmental vitiligo

  This trial tests whether different doses of GIA632 can safely help restore skin pigment in adults with non-segmental vitiligo.

  Recruiting at 85 sites Phase 2 Novartis · Birmingham, Alabama and 84 other locations · NCT07431177

• Phase 2 EI-001 for non-segmental vitiligo

  This trial will test whether the antibody drug EI-001 can help adults (18–65) with non‑segmental vitiligo regain skin pigment more than a placebo.

  Recruiting at 7 sites Phase 2 Elixiron Immunotherapeutics (Hong Kong) Ltd. · Huntington Beach, California and 7 other locations · NCT07223229

• VC005 tablets for people with non-segmental vitiligo

  This trial will test VC005 tablets to see if they safely help adults aged 18–70 with non-segmental vitiligo regain skin pigment.

  Recruiting Phase 2 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijng · NCT07172347

• Roflumilast 0.3% foam for children with non-segmental vitiligo

  This trial will try a roflumilast 0.3% topical foam to see if it helps children and teens (ages 2–17) with non-segmental vitiligo affecting small areas including the face.

  Recruiting Phase 2 Derm Texas, PLLC · Dallas, Texas · NCT07105254

• ICP-332 treatment for non-segmental vitiligo

  This trial will test whether oral ICP-332 tablets help people with non-segmental vitiligo (including adolescents in the Phase III part) who have at least 5% body surface area affected and facial involvement regain skin pigment better than placebo.

  Recruiting at 4 sites Phase 2/3 Beijing InnoCare Pharma Tech Co., Ltd. · Wuhu, Anhui and 44 other locations · NCT07047612

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.